Regencell Bioscience Holdings Limited Ordinary Shares is a drug manufacturers-specialty & generic business based in the US. Regencell Bioscience Holdings Limited Ordinary Shares shares (RGC) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Experienced Investors
Our top pick for
Large Accounts
| Latest market close | $17.00 |
|---|---|
| 52-week range | $6.00 - $59.00 |
| 50-day moving average | $21.75 |
| 200-day moving average | $17.66 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $17 from 2021-10-21
| 1 week (2021-10-15) | -8.80% |
|---|---|
| 1 month (2021-09-22) | -17.68% |
| 3 months (2021-07-22) | 87.64% |
| 6 months (2021-04-18) | N/A |
| 1 year (2020-10-18) | N/A |
|---|---|
| 2 years (2019-10-18) | N/A |
| 3 years (2018-10-18) | N/A |
| 5 years (2016-10-18) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | N/A |
| Market capitalisation | $212.6 million |
TTM: trailing 12 months
There are currently 25,120 Regencell Bioscience Holdings Limited Ordinary Shares shares held short by investors – that's known as Regencell Bioscience Holdings Limited Ordinary Shares's "short interest". This figure is 45% down from 45,697 last month.
There are a few different ways that this level of interest in shorting Regencell Bioscience Holdings Limited Ordinary Shares shares can be evaluated.
Regencell Bioscience Holdings Limited Ordinary Shares's "short interest ratio" (SIR) is the quantity of Regencell Bioscience Holdings Limited Ordinary Shares shares currently shorted divided by the average quantity of Regencell Bioscience Holdings Limited Ordinary Shares shares traded daily (recently around 418666.66666667). Regencell Bioscience Holdings Limited Ordinary Shares's SIR currently stands at 0.06. In other words for every 100,000 Regencell Bioscience Holdings Limited Ordinary Shares shares traded daily on the market, roughly 60 shares are currently held short.
To gain some more context, you can compare Regencell Bioscience Holdings Limited Ordinary Shares's short interest ratio against those of similar companies.
However Regencell Bioscience Holdings Limited Ordinary Shares's short interest can also be evaluated against the total number of Regencell Bioscience Holdings Limited Ordinary Shares shares, or, against the total number of tradable Regencell Bioscience Holdings Limited Ordinary Shares shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regencell Bioscience Holdings Limited Ordinary Shares's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Regencell Bioscience Holdings Limited Ordinary Shares shares in existence, roughly 0 shares are currently held short) or 0.0124% of the tradable shares (for every 100,000 tradable Regencell Bioscience Holdings Limited Ordinary Shares shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regencell Bioscience Holdings Limited Ordinary Shares.
Find out more about how you can short Regencell Bioscience Holdings Limited Ordinary Shares stock.
We're not expecting Regencell Bioscience Holdings Limited Ordinary Shares to pay a dividend over the next 12 months.
Regencell Bioscience Holdings Limited operates a traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.